Critical Flaws: New Alzheimer’s Drug Could Actually Be a Safety Risk
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, and financial connections between expert advisors and pharmaceutical companies. It was found that seven out…